Bray Christina Elaine 4

What Happened

• Christina Elaine Bray, a director of Biolargo, was granted a derivative award (stock option) covering 165,198 shares on 2026-06-30. The option was issued as payment for $18,750 in board fees under Biolargo’s 2024 Equity Incentive Plan. The filing lists the award as a derivative (grant/award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-02 (appears timely).
• Security: Option (derivative) covering 165,198 shares; transaction reported as type “A” (award/grant).
• Consideration: Issued in lieu of $18,750 in fees. The footnote explains the number of option shares equals the fees divided by the option’s exercise price; the filing itself does not state an exercise price. (Implied exercise price ≈ $18,750 ÷ 165,198 ≈ $0.1135/share based on the footnote math.)
• Shares owned after transaction: not specified in the provided filing details.
• Plan: Issued under the Issuer’s 2024 Equity Incentive Plan.

Context

• This was a compensation grant (option award) to a director, not an exercise or sale. Options give the right to buy shares in the future at the plan’s exercise price; they are common director compensation and do not by themselves indicate immediate buying or selling intent. Such awards can dilute existing holders if exercised, but they are routine for board service.